People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Healthtech, Other Technology, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evolent Health, Inc. | — | Healthtech | Series D+ | $433.3M | $9.8M | 2016 |
| Braze, Inc. | — | Other Technology | Series D+ | $289.5M | $1.3B | 2016 |
| RetireGo, Inc. | — | Other Technology | Series B | $40.9M | $138.8M | 2024 |
| Badgeville, Inc. | — | Other Technology | Series B | $36.5M | $761.4M | 2011 |
| Blackbird Health, Inc. | — | Healthtech | Series B | $22.8M | $176.9M | 2024 |
| Edgewater Networks, Inc. | — | Other Technology | Series A | $20.4M | $131.9M | 2009 |
| LeadCrunch Inc. | — | Other Technology | Series A | $17.5M | $292.7M | 2018 |
| Crio Inc. | — | Other Health Care | Series A | $14.9M | $12.8M | 2021 |
| Scout Labs, Inc. | — | Other | Series A | $4.0M | $60.8M | 2009 |
| Swarm Solutions, Inc. | — | Other | Seed | $3.4M | $64.1M | 2013 |
Tom Peterson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tom Peterson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Toth | 2 | 5 |
| John Johnson | 1 | 25 |
| Neeraj Agrawal | 1 | 17 |
| Paul Madera | 1 | 11 |
| Raymond Chang | 1 | 10 |
| Jed Katz | 1 | 10 |
| Chirag Shah | 1 | 10 |
| Tim Chang | 1 | 9 |
| Bruce Taragin | 1 | 9 |
| Jeff Crowe | 1 | 9 |
| Peter Grua | 1 | 7 |
| MATTHEW JACOBSON | 1 | 6 |
| Richard Harjes | 1 | 6 |
| Doug Pepper | 1 | 5 |
| Frank Williams | 1 | 5 |
| Amanda Reed | 1 | 5 |
| Bruce Felt | 1 | 5 |
| Daniel Beck | 1 | 4 |
| STEVE WIGGINTON | 1 | 4 |
| Mark Ghermezian | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.